PE20241730A1 - Compuestos y metodos para tratar la ataxia de friedreich - Google Patents

Compuestos y metodos para tratar la ataxia de friedreich

Info

Publication number
PE20241730A1
PE20241730A1 PE2024001532A PE2024001532A PE20241730A1 PE 20241730 A1 PE20241730 A1 PE 20241730A1 PE 2024001532 A PE2024001532 A PE 2024001532A PE 2024001532 A PE2024001532 A PE 2024001532A PE 20241730 A1 PE20241730 A1 PE 20241730A1
Authority
PE
Peru
Prior art keywords
terminus
ataxia
compounds
methods
fxn
Prior art date
Application number
PE2024001532A
Other languages
English (en)
Spanish (es)
Inventor
Aseem Ansari
Abhijit Bhat
Sean Jeffries
Pratik Shah
Chengzhi Zhang
Original Assignee
Design Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Design Therapeutics Inc filed Critical Design Therapeutics Inc
Publication of PE20241730A1 publication Critical patent/PE20241730A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PE2024001532A 2022-01-06 2023-01-06 Compuestos y metodos para tratar la ataxia de friedreich PE20241730A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263297090P 2022-01-06 2022-01-06
US202263382854P 2022-11-08 2022-11-08
PCT/US2023/010331 WO2023133284A2 (en) 2022-01-06 2023-01-06 Compounds and methods for treating friedreich's ataxia

Publications (1)

Publication Number Publication Date
PE20241730A1 true PE20241730A1 (es) 2024-08-19

Family

ID=87074158

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001532A PE20241730A1 (es) 2022-01-06 2023-01-06 Compuestos y metodos para tratar la ataxia de friedreich

Country Status (14)

Country Link
US (1) US20250109132A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460302A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502064A (cg-RX-API-DMAC7.html)
KR (1) KR20240138079A (cg-RX-API-DMAC7.html)
AU (1) AU2023205889A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246468A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002029A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010651A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240321A (cg-RX-API-DMAC7.html)
IL (1) IL314006A (cg-RX-API-DMAC7.html)
MX (1) MX2024008474A (cg-RX-API-DMAC7.html)
PE (1) PE20241730A1 (cg-RX-API-DMAC7.html)
TW (1) TW202334148A (cg-RX-API-DMAC7.html)
WO (1) WO2023133284A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
WO2025076181A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
EP4788669A1 (en) * 2023-10-03 2026-08-12 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
WO2025076219A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2015053413A1 (ja) * 2013-10-11 2015-04-16 千葉県 ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤
US11759533B2 (en) * 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
WO2020253711A1 (zh) * 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
JP7465945B2 (ja) * 2019-07-02 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Bet阻害剤としてのヘテロ環式化合物
CA3204523A1 (en) * 2021-01-08 2022-07-14 Aseem Ansari Methods and compounds for treating friedreich's ataxia

Also Published As

Publication number Publication date
IL314006A (en) 2024-08-01
CR20240321A (es) 2024-10-16
AU2023205889A1 (en) 2024-08-15
CO2024010651A2 (es) 2024-08-08
EP4460302A2 (en) 2024-11-13
US20250109132A1 (en) 2025-04-03
CA3246468A1 (en) 2023-07-13
MX2024008474A (es) 2024-07-12
EP4460302A4 (en) 2025-12-24
WO2023133284A3 (en) 2023-08-24
WO2023133284A2 (en) 2023-07-13
KR20240138079A (ko) 2024-09-20
CL2024002029A1 (es) 2024-11-04
TW202334148A (zh) 2023-09-01
JP2025502064A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
CO2024010651A2 (es) Compuestos y métodos para tratar la ataxia de friedreich
Müller et al. Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli
PE20231851A1 (es) Proteinas que se unen a nkg2d, cd16 y clec12a
ATE544473T1 (de) Chimäre moleküle zur modulation der genexpression
CN115190884B (zh) 新型细胞递送方法
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
UY30497A1 (es) Proteinas de fusion comprendiendo una exendina-4, composiciones y aplicaciones
Qiu et al. A diazirine-based nucleoside analogue for efficient DNA interstrand photocross-linking
BR112023025331A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
NO20044628L (no) Immunglobulindomene som inneholder celleoverflategjenkjennende molekyler
US10400274B2 (en) Fluorogenic probes and their use in quantitative detection of target RNA sequences
Falconer et al. Collagenolytic matrix metalloproteinases antagonize proteinase-activated receptor-2 activation, providing insights into extracellular matrix turnover
US20230002442A1 (en) An activated cysteine-directed polypeptide ligation technique
MX2023008153A (es) Metodos y compuestos para tratar la ataxia de friedreich.
PE20240369A1 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y metodos de uso de estos
US7056656B1 (en) Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
PE20221783A1 (es) Anticuerpos anti-axl y composiciones
CO2025015252A2 (es) Molécula de ácido nucleico y métodos
EP4234550A3 (en) Methods and compounds for the treatment of genetic disease
PE20240233A1 (es) Fracciones que prolongan la semivida y metodos de uso de estas
AR128224A1 (es) Compuestos y métodos para tratar la ataxia de friedreich
ATE439856T1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
MX2021004370A (es) Creacion de codigos de barras de acidos nucleicos.
PE20220604A1 (es) Molecula de acido nucleico para el tratamiento de la trombocitopenia y uso de la misma
Cao et al. Orientation and Affinity of HIV-1 Tat Fragments in Tat− TAR Complex Determined by Fluorescence Resonance Energy Transfer